media Media
Healthcare Industry Media Coverage2017-09-13T20:18:16+00:00

Media Coverage

Want to Try Emgality? What You Should Know

From: MigraineAgain By: Lori Smith         At this time, there is no safety reason for not allowing people to try both Botox and Emgality at the same time. According to Virginia Schobel, Neurology Franchise Head at Spherix Global Insights...(read more).

September 28, 2020|

Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds

From: Multiple Sclerosis News Today By: Marta Figueiredo       Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights...(read more).

September 22, 2020|

Newest Oral DMTs Haven’t Yet Made a Big Impact in the MS World

From: MDedge Neurology By: Bruce Jancin The three oral disease-modifying therapies (DMTs) for multiple sclerosis (MS) approved last year in the United States haven’t made a big splash in the marketplace. So far, it’s more like a ripple, according to a study of neurologists’ prescribing patterns. “The recently approved therapies will initially be niched as later-line options,” predicted Virginia R. Schobel, MSc, nephrology franchise head at Spherix Global Insights... (read more).

June 5, 2020|

Survey Finds Cimzia Prescriptions for nr-axSpA on the Rise in US

From: Ankylosing Spondylitis News By: Patricia Inacio, PhD.         According to Spherix Global Insights' survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread use for Cimzia...(read more).

May 18, 2020|
Go to Top